Published in Women's Health Weekly, March 18th, 2004
Introgen has completed a phase I/II clinical trial with INGN 241 and the data indicates that the therapy has demonstrated activity as a monotherapy in several cancer indications. Due to the multifunctional activity of mda-7/IL-24, which acts as a tumor suppressor, a potent inhibitor of angiogenesis, and an immunostimulating cytokine, INGN 241 may have broad utility as a monotherapy or as a component of combination regimens in a variety of cancer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.